14
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic

      research-article
      , MD, MBA 1 , 2 , , , PhD 3 , , PhD, MBA 3 , , PhD 4 , , MD, PhD 1 , 2 , 5 , , BS 3 , , PhD 1 , 2
      JAMA Internal Medicine
      American Medical Association

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Key Points

          Question

          Are hospital outcomes for patients with coronavirus disease 2019 (COVID-19) improving?

          Findings

          In this cohort study of 38 517 adults who were admitted with COVID-19 to 955 US hospitals, rates of 30-day mortality or referral to hospice varied from 9.06% to 15.65% in the best- and worst-performing quintiles. In the early months of the pandemic, 94% of hospitals in a subset of 398 improved by at least 25%, and the strongest determinant of improvements in hospital-level outcome was a decline in community rates of infection.

          Meaning

          All else being equal, COVID-19 mortality in hospitals seems to be lower when the prevalence of COVID-19 in their surrounding communities is lower.

          Abstract

          Importance

          It is unknown how much the mortality of patients with coronavirus disease 2019 (COVID-19) depends on the hospital that cares for them, and whether COVID-19 hospital mortality rates are improving.

          Objective

          To identify variation in COVID-19 mortality rates and how those rates have changed over the first months of the pandemic.

          Design, Setting, and Participants

          This cohort study assessed 38 517 adults who were admitted with COVID-19 to 955 US hospitals from January 1, 2020, to June 30, 2020, and a subset of 27 801 adults (72.2%) who were admitted to 398 of these hospitals that treated at least 10 patients with COVID-19 during 2 periods (January 1 to April 30, 2020, and May 1 to June 30, 2020).

          Exposures

          Hospital characteristics, including size, the number of intensive care unit beds, academic and profit status, hospital setting, and regional characteristics, including COVID-19 case burden.

          Main Outcomes and Measures

          The primary outcome was the hospital’s risk-standardized event rate (RSER) of 30-day in-hospital mortality or referral to hospice adjusted for patient-level characteristics, including demographic data, comorbidities, community or nursing facility admission source, and time since January 1, 2020. We examined whether hospital characteristics were associated with RSERs or their change over time.

          Results

          The mean (SD) age among participants (18 888 men [49.0%]) was 70.2 (15.5) years. The mean (SD) hospital-level RSER for the 955 hospitals was 11.8% (2.5%). The mean RSER in the worst-performing quintile of hospitals was 15.65% compared with 9.06% in the best-performing quintile (absolute difference, 6.59 percentage points; 95% CI, 6.38%-6.80%; P < .001). Mean RSERs in all but 1 of the 398 hospitals improved; 376 (94%) improved by at least 25%. The overall mean (SD) RSER declined from 16.6% (4.0%) to 9.3% (2.1%). The absolute difference in rates of mortality or referral to hospice between the worst- and best-performing quintiles of hospitals decreased from 10.54 percentage points (95% CI, 10.03%-11.05%; P < .001) to 5.59 percentage points (95% CI, 5.33%-5.86%; P < .001). Higher county-level COVID-19 case rates were associated with worse RSERs, and case rate declines were associated with improvement in RSERs.

          Conclusions and Relevance

          Over the first months of the pandemic, COVID-19 mortality rates in this cohort of US hospitals declined. Hospitals did better when the prevalence of COVID-19 in their surrounding communities was lower.

          Abstract

          This cohort study examines variations in COVID-19 mortality rates and over the first 6 months of the pandemic.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: not found
          • Article: not found

          STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial

            Remdesivir demonstrated clinical benefit in a placebo-controlled trial in patients with severe coronavirus disease 2019 (COVID-19), but its effect in patients with moderate disease is unknown.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Comorbidity Measures for Use with Administrative Data

                Bookmark

                Author and article information

                Journal
                JAMA Intern Med
                JAMA Intern Med
                JAMA Intern Med
                JAMA Internal Medicine
                American Medical Association
                2168-6106
                2168-6114
                April 2021
                22 December 2020
                22 December 2020
                : 181
                : 4
                : 471-478
                Affiliations
                [1 ]Division of General Internal Medicine, University of Pennsylvania, Philadelphia
                [2 ]Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia
                [3 ]UnitedHealth Group, Minnetonka, Minnesota
                [4 ]Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia
                [5 ]Cpl Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania
                Author notes
                Article Information
                Accepted for Publication: November 14, 2020.
                Published Online: December 22, 2020. doi:10.1001/jamainternmed.2020.8193
                Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Asch DA et al. JAMA Internal Medicine.
                Corresponding Author: David A. Asch, MD, Center for Health Care Innovation, 3400 Civic Center Blvd, PCAM South Tower 14-171, Philadelphia, PA 19104 ( asch@ 123456wharton.upenn.edu ).
                Author Contributions: Dr Islam and Mr Buresh had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
                Concept and design: All authors.
                Acquisition, analysis, or interpretation of data: All authors.
                Drafting of the manuscript: All authors.
                Critical revision of the manuscript for important intellectual content: All authors.
                Statistical analysis: Sheils, Islam, Werner, Buresh, Chen.
                Supervision: Sheils, Werner, Doshi.
                Conflict of Interest Disclosures: Dr Doshi reported personal fees from AbbVie, Boehringer Ingelheim, Janssen, Kite Pharma, and Merck and grants from AbbVie, Janssen, Novartis, Merck, Pfizer, PhRMA, Regeneron, and Sanofi and outside the submitted work. No other disclosures were reported.
                Article
                ioi200109
                10.1001/jamainternmed.2020.8193
                7756246
                33351068
                648da8ec-b755-43db-aa03-3df1d3e1fd8d
                Copyright 2020 Asch DA et al. JAMA Internal Medicine.

                This is an open access article distributed under the terms of the CC-BY License.

                History
                : 14 October 2020
                : 14 November 2020
                Categories
                Research
                Research
                Original Investigation
                Online First

                Comments

                Comment on this article